These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

481 related items for PubMed ID: 29844695

  • 1. Role of biologics and biosimilars in inflammatory bowel disease: current trends and future perspectives.
    Rawla P, Sunkara T, Raj JP.
    J Inflamm Res; 2018; 11():215-226. PubMed ID: 29844695
    [Abstract] [Full Text] [Related]

  • 2. Drugs for inflammatory bowel disease.
    Med Lett Drugs Ther; 2023 Jul 10; 65(1680):105-112. PubMed ID: 37418329
    [No Abstract] [Full Text] [Related]

  • 3. Biologics in inflammatory bowel disease: what are the data?
    Côté-Daigneault J, Bouin M, Lahaie R, Colombel JF, Poitras P.
    United European Gastroenterol J; 2015 Oct 10; 3(5):419-28. PubMed ID: 26535119
    [Abstract] [Full Text] [Related]

  • 4. Drugs for inflammatory bowel disease.
    Med Lett Drugs Ther; 2018 Jul 02; 60(1550):107-114. PubMed ID: 30036352
    [No Abstract] [Full Text] [Related]

  • 5.
    Chao YS, Loshak H.
    ; 2019 04 17. PubMed ID: 31693324
    [Abstract] [Full Text] [Related]

  • 6. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
    Magro F, Portela F.
    BioDrugs; 2010 Dec 14; 24 Suppl 1():3-14. PubMed ID: 21175228
    [Abstract] [Full Text] [Related]

  • 7. Predictors of Primary Response to Biologic Treatment [Anti-TNF, Vedolizumab, and Ustekinumab] in Patients With Inflammatory Bowel Disease: From Basic Science to Clinical Practice.
    Gisbert JP, Chaparro M.
    J Crohns Colitis; 2020 Jun 19; 14(5):694-709. PubMed ID: 31777929
    [Abstract] [Full Text] [Related]

  • 8. Risankizumab (Skyrizi) - An IL-23 antagonist for Crohn's disease.
    Med Lett Drugs Ther; 2022 Dec 26; 64(1666):153-157. PubMed ID: 36542348
    [No Abstract] [Full Text] [Related]

  • 9. Comparison table: some drugs for inflammatory bowel disease.
    Med Lett Drugs Ther; 2018 Jul 02; 60(1550):e117-e122. PubMed ID: 30036356
    [No Abstract] [Full Text] [Related]

  • 10. Advances in the development of new biologics in inflammatory bowel disease.
    Ungar B, Kopylov U.
    Ann Gastroenterol; 2016 Jul 02; 29(3):243-8. PubMed ID: 27366024
    [Abstract] [Full Text] [Related]

  • 11. Biosimilars in the Treatment of Inflammatory Bowel Disease: Supporting Evidence in 2017.
    Scott FI, Lichtenstein GR.
    Curr Treat Options Gastroenterol; 2018 Mar 02; 16(1):147-164. PubMed ID: 29492747
    [Abstract] [Full Text] [Related]

  • 12. A review of ophthalmic manifestations of inflammatory bowel disease and associated treatments.
    Janardhana P, Al-Kadhi S.
    Curr Opin Ophthalmol; 2021 Nov 01; 32(6):549-554. PubMed ID: 34506327
    [Abstract] [Full Text] [Related]

  • 13. Biologic therapies in inflammatory bowel disease.
    Cohen LB, Nanau RM, Delzor F, Neuman MG.
    Transl Res; 2014 Jun 01; 163(6):533-56. PubMed ID: 24467968
    [Abstract] [Full Text] [Related]

  • 14. Expanded table: Some drugs for inflammatory bowel disease.
    Med Lett Drugs Ther; 2023 Jul 10; 65(1680):e115-e119. PubMed ID: 37418332
    [No Abstract] [Full Text] [Related]

  • 15.
    Ringerike T, Elvsaas IKØ, Coll P, Lundin KEA, Movik E, Gjertsen MK.
    ; 2008 12 10. PubMed ID: 29320135
    [Abstract] [Full Text] [Related]

  • 16. Exposure Concentrations of Infants Breastfed by Women Receiving Biologic Therapies for Inflammatory Bowel Diseases and Effects of Breastfeeding on Infections and Development.
    Matro R, Martin CF, Wolf D, Shah SA, Mahadevan U.
    Gastroenterology; 2018 Sep 10; 155(3):696-704. PubMed ID: 29857090
    [Abstract] [Full Text] [Related]

  • 17. Current, new and future biological agents on the horizon for the treatment of inflammatory bowel diseases.
    Amiot A, Peyrin-Biroulet L.
    Therap Adv Gastroenterol; 2015 Mar 10; 8(2):66-82. PubMed ID: 25729432
    [Abstract] [Full Text] [Related]

  • 18. Upadacitinib (Rinvoq): A second JAK inhibitor for ulcerative colitis.
    Med Lett Drugs Ther; 2022 Sep 05; 64(1658):142-144. PubMed ID: 36094554
    [No Abstract] [Full Text] [Related]

  • 19. Biosimilars of Adalimumab in Inflammatory Bowel Disease: Are we Ready for that?
    Argollo M, Fiorino G, Gilardi D, Furfaro F, Roda G, Loy L, Allocca M, Peyrin-Biroulet L, Danese S.
    Curr Pharm Des; 2019 Sep 05; 25(1):7-12. PubMed ID: 30864505
    [Abstract] [Full Text] [Related]

  • 20. A Review on the Use of Anti-TNF in Children and Adolescents with Inflammatory Bowel Disease.
    Aardoom MA, Veereman G, de Ridder L.
    Int J Mol Sci; 2019 May 23; 20(10):. PubMed ID: 31126015
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.